Genprex is a biotechnology business based in the US. Genprex shares (GNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.34 – a decrease of 3.37% over the previous week. Genprex employs 21 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.34 |
|---|---|
| 52-week range | $0.28 - $15.15 |
| 50-day moving average | $0.77 |
| 200-day moving average | $3.31 |
| Wall St. target price | $8.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-15.60 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3388 from 2024-10-11
| 1 week (2024-10-07) | -3.17% |
|---|---|
| 1 month (2024-09-13) | -19.33% |
| 3 months (2024-07-12) | -82.35% |
| 6 months (2024-04-12) | -87.36% |
| 1 year (2023-10-13) | 4.25% |
|---|---|
| 2 years (2022-10-14) | -74.53% |
| 3 years (2021-10-14) | 2.46 |
| 5 years (2019-10-14) | 0.5048 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -145.94% |
| Return on equity TTM | -318.88% |
| Profit margin | 0% |
| Book value | $1.70 |
| Market Capitalization | $907,542 |
TTM: trailing 12 months
We're not expecting Genprex to pay a dividend over the next 12 months.
Genprex's shares were split on a 1:40 basis on 1 February 2024. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genprex shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Genprex shares which in turn could have impacted Genprex's share price.
Over the last 12 months, Genprex's shares have ranged in value from as little as $0.2806 up to $15.152. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genprex's is -0.598. This would suggest that Genprex's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Genprex has bucked the trend.
Genprex, Inc. , a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.